Dr. Reddy's anti-diabetes compound clears phase 1 trials
Novo Nordisk of Denmark has cleared the anti-diabetes compound DRF- 2593 of Dr Reddy's Laboratories Ltd(DRL) for its entry into phase II deveopment. This molecule was originally licensed by Novo